Difference between revisions of "Thromboelastography"
Jump to navigation
Jump to search
(Thromboelastography) |
(+Normal) |
||
Line 4: | Line 4: | ||
}} | }} | ||
==Interpretation== | ==Interpretation== | ||
+ | [[Image:Thromboelastography parameters.png|thumb|300px|Normal thromboelastogram with parameters.]] | ||
+ | Parameters derived from thromboelastography are mainly:<ref name="pmid32988649">{{cite journal| author=Tyler PD, Yang LM, Snider SB, Lerner AB, Aird WC, Shapiro NI| title=New Uses for Thromboelastography and Other Forms of Viscoelastic Monitoring in the Emergency Department: A Narrative Review. | journal=Ann Emerg Med | year= 2021 | volume= 77 | issue= 3 | pages= 357–366 | pmid=32988649 | doi=10.1016/j.annemergmed.2020.07.026 | pmc= | doi-access=free }} </ref> | ||
+ | * '''R time''': Time to initial clot formation (that is, amplitude deviation from baseline) | ||
+ | * '''K time''': Time from initial clot formation until reaching 20 mm in amplitude | ||
+ | * '''Alpha angle (α)''': Angle between the baseline at initial clot formation, and a tangent line that intersects the tracing curve. | ||
+ | * '''Maximum amplitude (MA)''': Maximum deviation of tracing to baseline. | ||
+ | * '''A<sub>30</sub>''': Amplitude 30 minutes after reaching maximum amplitude. | ||
+ | |||
Following are examples of thromboelastography patterns and recommended treatments.<ref>{{cite journal| author=Collins S, MacIntyre C, Hewer I| title=Thromboelastography: Clinical Application, Interpretation, and Transfusion Management. | journal=AANA J | year= 2016 | volume= 84 | issue= 2 | pages= 129–34 | pmid=27311154 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27311154 }}</ref><ref>{{cite journal| author=Kreitzer NP, Bonomo J, Kanter D, Zammit C| title=Review of Thromboelastography in Neurocritical Care. | journal=Neurocrit Care | year= 2015 | volume= 23 | issue= 3 | pages= 427–33 | pmid=26275677 | doi=10.1007/s12028-015-0187-9 | pmc= | s2cid=29854774 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26275677 }}</ref> | Following are examples of thromboelastography patterns and recommended treatments.<ref>{{cite journal| author=Collins S, MacIntyre C, Hewer I| title=Thromboelastography: Clinical Application, Interpretation, and Transfusion Management. | journal=AANA J | year= 2016 | volume= 84 | issue= 2 | pages= 129–34 | pmid=27311154 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27311154 }}</ref><ref>{{cite journal| author=Kreitzer NP, Bonomo J, Kanter D, Zammit C| title=Review of Thromboelastography in Neurocritical Care. | journal=Neurocrit Care | year= 2015 | volume= 23 | issue= 3 | pages= 427–33 | pmid=26275677 | doi=10.1007/s12028-015-0187-9 | pmc= | s2cid=29854774 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26275677 }}</ref> | ||
{|class=wikitable | {|class=wikitable |
Revision as of 14:47, 28 October 2022
Author:
Mikael Häggström, M.D. [note 1]
Interpretation
Parameters derived from thromboelastography are mainly:[1]
- R time: Time to initial clot formation (that is, amplitude deviation from baseline)
- K time: Time from initial clot formation until reaching 20 mm in amplitude
- Alpha angle (α): Angle between the baseline at initial clot formation, and a tangent line that intersects the tracing curve.
- Maximum amplitude (MA): Maximum deviation of tracing to baseline.
- A30: Amplitude 30 minutes after reaching maximum amplitude.
Following are examples of thromboelastography patterns and recommended treatments.[2][3]
Condition | Appearance | Main treatment |
---|---|---|
Normal | ||
Hemodilution or clotting factor deficiency | Fresh frozen plasma | |
Fibrinogen deficiency | Cryoprecipitate | |
Low or dysfunctional platelets | Platelets | |
Thrombosis | Anticoagulant | |
Primary fibrinolysis | Antifibrinolytics or tranexamic acid | |
Secondary fibrinolysis | Treating disseminated intravascular coagulation |
Notes
- ↑ For a full list of contributors, see article history. Creators of images are attributed at the image description pages, seen by clicking on the images. See Patholines:Authorship for details.
Main page
References
- ↑ Tyler PD, Yang LM, Snider SB, Lerner AB, Aird WC, Shapiro NI (2021). "New Uses for Thromboelastography and Other Forms of Viscoelastic Monitoring in the Emergency Department: A Narrative Review. ". Ann Emerg Med 77 (3): 357–366. doi: . PMID 32988649.
- ↑ Collins S, MacIntyre C, Hewer I (2016). "Thromboelastography: Clinical Application, Interpretation, and Transfusion Management. ". AANA J 84 (2): 129–34. PMID 27311154. Archived from the original. .
- ↑ Kreitzer NP, Bonomo J, Kanter D, Zammit C (2015). "Review of Thromboelastography in Neurocritical Care. ". Neurocrit Care 23 (3): 427–33. doi: . PMID 26275677. Archived from the original. .
Image sources